| All Releases |
|---|
 |
EpiCept Announces Receipt of Nasdaq Notice
Apr 18, 2008
|
10.5 KB
|
| |
TARRYTOWN, N.Y., Apr 18, 2008 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has received a letter from the Nasdaq Listings Qualification Department stating that EpiCept is not in compliance with the continued listing requirements of The Nasdaq Capital Market because the bi...
|
|
|
EpiCept Announces Multiple Presentations on ASAP Technology at American Association of Cancer Research Annual Meeting
Apr 8, 2008
|
12.3 KB
|
| |
TARRYTOWN, N.Y., Apr 08, 2008 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will present new drug discovery advances emanating from its Anti-cancer Screening Apoptosis Platform (ASAP) as well as structure activity relationship studies from its clinical-stage apoptosis indu...
|
|
|
EpiCept Announces Receipt of Nasdaq Notice
Apr 7, 2008
|
9.9 KB
|
| |
TARRYTOWN, N.Y., Apr 07, 2008 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has received a letter from the Nasdaq Listings Qualification Department stating that EpiCept is not in compliance with the continued listing requirements of The Nasdaq Capital Market because the ma...
|
|
|
EpiCept Announces Positive Clinical Data from EPC2407 Phase I Cancer Trial
Apr 7, 2008
|
13.6 KB
|
| |
TARRYTOWN, N.Y., Apr 07, 2008 (BUSINESS WIRE) -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today released clinical study results from the Phase I trial of EPC2407, which provided visible evidence of vascular disruptive activity. EPC2407 is EpiCept's novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the ...
|
|
|
EpiCept Announces Opinion by European Regulatory Authority on Ceplene(R)
Mar 20, 2008
|
12.1 KB
|
| |
TARRYTOWN, N.Y., Mar 20, 2008 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued, as expected following the trend vote announced last mo...
|
|
|
EpiCept Corporation Announces Pricing of Public Offering
Mar 6, 2008
|
10.5 KB
|
| |
TARRYTOWN, N.Y., Mar 06, 2008 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today the pricing of a public offering of approximately 5.4 million shares of its common stock at $0.9225 per share and five-year warrants to purchase up to approximately 2.7 million shares of common stock at an...
|
|
|
EpiCept Earns Milestone Payment Due to Progress in Phase II Trial for Azixa(TM) in Melanoma Metastases
Mar 6, 2008
|
12.5 KB
|
| |
TARRYTOWN, N.Y., Mar 06, 2008 (BUSINESS WIRE) -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has earned a milestone payment from Myriad Genetics, Inc., for progress due to patient dosing in a Phase II trial being conducted by Myriad for Azixa(TM) (MPC-6827) in melanoma that has spread to the brain. Azixa is an...
|
|
|
EpiCept Announces Resignation of Board Member Gert Caspritz
Mar 5, 2008
|
9.8 KB
|
| |
TARRYTOWN, N.Y., Mar 05, 2008 (BUSINESS WIRE) -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Gert Caspritz has resigned from the Company's Board of Directors, effective March 6, 2008. Dr. Caspritz, a general partner of TVM Capital, has been a member of the Company's Board since 1999 and served as EpiCept's Chairm...
|
|
|
EpiCept to Host Q&A Conference Call March 3 at 10 A.M. Eastern Time
Feb 29, 2008
|
10.2 KB
|
| |
TARRYTOWN, N.Y., Feb 29, 2008 (BUSINESS WIRE) -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced it will host an investment community conference call on Monday, March 3, 2008 beginning at 10:00 a.m. Eastern time. This conference call is being held subsequent to an EpiCept conference call on Friday, February 29, 2008 to di...
|
|
|
EpiCept Corporation Reports Fourth Quarter and Full Year 2007 Operating and Financial Results
Feb 29, 2008
|
21.1 KB
|
| |
TARRYTOWN, N.Y. (February 29, 2008) - EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced operating and financial results for the fourth quarter and year ended December 31, 2007. For the fourth quarter and full year 2007, EpiCept's net loss attributable to common stockholders was $6.3 million, or $0.15 per share, a...
|
|
|
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Feb 27, 2008
|
11.8 KB
|
| |
TARRYTOWN, N.Y., Feb 27, 2008 (BUSINESS WIRE) -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that the Company recently presented at the Oral Explanation meeting to the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), regarding the remaini...
|
|
|
EpiCept to Report Fourth Quarter and Full-Year 2007 Operating and Financial Results on February 29, 2008
Feb 26, 2008
|
10.2 KB
|
| |
TARRYTOWN, N.Y., Feb 26, 2008 (BUSINESS WIRE) -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will host a conference call to discuss fourth quarter and full-year 2007 operating and financial results on Friday, February 29, 2008 at 9:00 a.m. Eastern time. The call will follow the release of these financial resul...
|
|
|
EpiCept Corporation to Present at the 10th Annual BIO CEO & Investor Conference
Feb 8, 2008
|
9.8 KB
|
| |
TARRYTOWN, N.Y., Feb 08, 2008 (BUSINESS WIRE) -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Jack Talley, President and CEO, will be presenting at the 10th Annual BIO CEO & Investor Conference on Wednesday, February 13, 2008 at 1:15 p.m. Eastern Time in the Park Avenue Suite of the Waldorf Astoria Hotel in New Yo...
|
|
|
EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
Feb 7, 2008
|
10.6 KB
|
| |
TARRYTOWN, N.Y., Feb 07, 2008 (BUSINESS WIRE) -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced preliminary results from its Phase II "Neuracept" trial for EpiCept™ NP-1 Cream in patients suffering from diabetic peripheral neuropathy (DPN). All pain scores measured trended in favor ...
|
|
|
EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream
Jan 22, 2008
|
10.3 KB
|
| |
TARRYTOWN, N.Y., Jan 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today provided updates on the regulatory and clinical status of Ceplene(TM) (histamine dihydrochloride) and EpiCept(TM) NP-1 Cream.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
EpiCep...
|
|
|
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Dec 10, 2007
|
13.9 KB
|
| |
TARRYTOWN, N.Y., Dec 10, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today released new clinical data that demonstrate a durable improvement in leukemia-free survival (LFS) over five years among Acute Myeloid Leukemia (AML) patients who receive post-consolidation immunotherapy wi...
|
|
|
EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
Dec 5, 2007
|
9.2 KB
|
| |
TARRYTOWN, N.Y., Dec 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Jack Talley, President and CEO, will present a company overview at the New York Society of Security Analysts ("NYSSA") 11th Annual Biotech & Specialty Pharma Conference on December 12, 2007 ...
|
|
|
EpiCept Corporation Announces Pricing of Public Offering
Dec 4, 2007
|
9.6 KB
|
| |
TARRYTOWN, N.Y., Dec 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today the pricing of a public offering of 3,333,333 million shares of its common stock at $1.50 per share and five-year warrants to purchase up to approximately 1,666,667 million shares of common stock...
|
|
|
EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
Dec 4, 2007
|
11.3 KB
|
| |
TARRYTOWN, N.Y., Dec 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it will be presenting new clinical data for Ceplene (histamine dihydrochloride) at the upcoming 49th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Geor...
|
|
|
Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
Dec 3, 2007
|
10.8 KB
|
| |
TARRYTOWN, N.Y., Dec 03, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has completed patient enrollment in the Phase IIb "Neuracept" trial for EpiCept(TM) NP-1 cream. EpiCept NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitrip...
|
|
|
